NCT07541092

Brief Summary

We believe that the design of the Optrell™ mapping catheter with TRUEref technology allows for faster and more accurate mapping not only due to narrow electrode spacing but also due to the ability to achieve simultaneous contact of multiple bipoles with the surface of the papillary muscle. Simultaneous mapping of multiple sites on the same surface will allow operators to appreciate small activation differences that typically exist between neighboring sites during papillary muscle ventricular arrhythmias. In addition, the position of the Optrell™ mapping catheter on the papillary muscle allows the mapping catheter to move with the papillary muscle rendering a more accurate allocation of the activation time to the surface of the papillary muscle. We also believe that optimal positioning between the Optrell™ mapping catheter and papillary muscles can be assisted by using intracardiac echocardiography. The goal of the study is to explore the utility and superiority of a specific mapping catheter, the Optrell™ mapping catheter with TRUEref.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
33mo left

Started Dec 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress34%
Dec 2024Dec 2028

Study Start

First participant enrolled

December 30, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 14, 2025

Completed
11 months until next milestone

First Posted

Study publicly available on registry

April 21, 2026

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2028

Last Updated

April 21, 2026

Status Verified

April 1, 2026

Enrollment Period

4 years

First QC Date

May 14, 2025

Last Update Submit

April 17, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Evaluate acute success in eliminating premature ventricular contractions

    During procedure

  • Evaluate success at 3 months follow up in eliminating premature ventricular contractions

    At 3 months follow post-procedure

Interventions

The Optrell™ mapping catheter with TRUEref technology is device that is used as an option during ablation of premature ventricular contractions originating from the papillary muscles.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients aged 18-75 diagnosed with ventricular arrhythmias.

You may qualify if:

  • Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements
  • Patient is not cognitively impaired, pregnant, prisoner, employed by Northwell, uninsured, or a student
  • Age 18-75 years old with the ability to consent for the procedure
  • Patient is consented within the enrollment window of the therapy received, as applicable
  • Patients with frequent (\>10%) or symptomatic PVCs with ECG morphology consistent with papillary muscle origin.
  • Papillary muscle PVCs in setting of cardiomyopathy.
  • Patients prescribed by their treating physician to undergo the procedure with the Optrell™ mapping catheter as part of routine clinical care.
  • Patient demonstrates proficiency in the English language; reading, writing, and conversational

You may not qualify if:

  • Patient who is, or is expected to be, inaccessible for follow-up
  • Participation is excluded by local law
  • Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound the study results
  • Unable to consent
  • PVC from site other than papillary muscle
  • Acute coronary syndrome
  • Congestive heart failure in acute decompensation
  • Rapid atrial fibrillation
  • Requiring ventricular pacing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Long Island Jewish Medical Center

New Hyde Park, New York, 11040, United States

RECRUITING

Study Officials

  • Haisam Ismail, MD

    Northwell Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Salome Elia Reddy

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2025

First Posted

April 21, 2026

Study Start

December 30, 2024

Primary Completion (Estimated)

December 30, 2028

Study Completion (Estimated)

December 30, 2028

Last Updated

April 21, 2026

Record last verified: 2026-04

Locations